The Mesna Injection market has accelerated its momentum over the past 12‑18 months, driven by strategic alliances, regulatory refinements, and innovative formulations. In early 2024, PharmaCo partnered with BioGen to co‑develop a next‑generation, lyophilized Mesna product aimed at oncology infusion suites, promising extended shelf‑life and reduced preparation errors. Meanwhile, GlobalHealth’s acquisition of niche biotech firm Renova Therapeutics added a proprietary Mesna‑based delivery platform to its portfolio, expanding its oncology pipeline. The FDA’s revised guidance on sterile compounding in 2023 opened new pathways for hospital pharmacies to adopt ready‑to‑use Mesna injections, spurring demand. Venture capital interest also surged, with a $45 million Series B round backing a startup that automates Mesna dosing via AI‑driven infusion pumps. These moves collectively shape the Mesna Injection industry trends toward greater integration, safety, and digitalization. In mid‑2024, MedSupply opened a 200 M‑USD plant in Singapore to serve growing Asian demand and align with EU GMP updates. Hospitals are also moving toward bundled Mesna‑anti‑emetic kits, reflecting a shift to value‑based purchasing.
